Small, Elan, Caleb Phillips, William Bunzel, Lakota Cleaver, Nishant Joshi, Laurel Gardner, Rony Maharjan, and James Marvel. Prior ambulatory mild coronavirus disease 2019 does not increase risk of acute mountain sickness. High Alt Med Biol. 24:201–208, 2023.
Background:
Given its long-term morbidity, understanding how prior coronavirus disease 2019 (COVID-19) may affect acute mountain sickness (AMS) susceptibility is important for preascent risk stratification. The objective of this study was to examine if prior COVID-19 impacts risk of AMS.
Materials and Methods:
This was a prospective observational study conducted in Lobuje (4,940 m) and Manang (3,519 m), Nepal, from April to May 2022. AMS was defined by the 2018 Lake Louise Questionnaire criteria. COVID-19 severity was defined using the World Health Organization-developed criteria.
Results:
In the Lobuje cohort of 2,027, 46.2% of surveyed individuals reported history of COVID-19, with 25.7% AMS point-prevalence. There was no significant relationship between prior ambulatory mild COVID-19 and AMS (p = 0.6) or moderate AMS (p = 1.0). In the Manang cohort of 908, 42.8% reported history of COVID-19, with 14.7% AMS point-prevalence. There was no significant relationship between prior ambulatory mild COVID-19 and AMS (p = 0.3) or moderate AMS (p = 0.4). Average months since COVID-19 was 7.4 (interquartile range [IQR] 3–10) for Lobuje, 6.2 (IQR 3–6) for Manang. Both cohorts rarely exhibited moderate COVID-19 history.
Conclusions:
Prior ambulatory mild COVID-19 was not associated with increased risk of AMS and should not preclude high-altitude travel.
Get full access to this article
View all access options for this article.
References
1.
AggarwalG, CheruiyotI, AggarwalS, WongJ, LippiG, LavieCJ, HenryBM, and Sanchis-GomarF. (2020). Association of cardiovascular disease with coronavirus disease 2019 (COVID-19) severity: A meta-analysis. Curr Problems Cardiol, 45:100617.
2.
Arias-ReyesC, Zubieta-DeUriosteN, Poma-MachicaoL, Aliaga-RaduanF, Carvajal-RodriguezF, DutschmannM, Schneider-GasserEM, Zubieta-CallejaG, and SolizJ. (2020). Does the pathogenesis of SARS-CoV-2 virus decrease at high-altitude?. Respir Physiol Neurobiol, 277:103443.
3.
BergerMM, HackettPH, and BärtschP. (2020). No relevant analogy between COVID-19 and acute mountain sickness. High Alt Med Biol, 21:315–318.
4.
BircherHP, EichenbergerU, MaggioriniM, OelzO, and BärtschP. (1994). Relationship of mountain sickness to physical fitness and exercise intensity during ascent. J Wilderness Med, 5:302–311.
5.
BursacZ, GaussCH, WilliamsDK, and HosmerDW. (2008). Purposeful selection of variables in logistic regression. Source Code Biol Med, 3:17.
6.
ChristensenCC, RygMS, RefvemOK, and SkjønsbergOH. (2002). Effect of hypobaric hypoxia on blood gases in patients with restrictive lung disease. Eur Respir J, 20:300–305.
Cornwell WKIII, BaggishAL, BhattaYKD, BrosnanMJ, DehnertC, GusehJS, HammerD, LevineBD, ParatiG, and WolfelEE. (2021). Clinical implications for exercise at altitude among individuals with cardiovascular disease: A scientific statement from the american heart association. J Am Heart Assoc, 10:e023225.
9.
CrameriGAG, BieleckiM, ZüstR, BuehrerTW, StangaZ, and DeuelJW. (2020). Reduced maximal aerobic capacity after COVID-19 in young adult recruits, Switzerland, May 2020. Euro Surveill, 25:2001542.
10.
DehnertC, LuksAM, SchendlerG, MenoldE, BergerMM, MairbaurlH, FaoroV, BaileyDM, CastellC, HahnG, VockP, SwensonER, and BärtschP. (2010). No evidence for interstitial lung oedema by extensive pulmonary function testing at 4,559 m. Eur Respir J, 35:812–820.
11.
GandhiS, SrivastavaAK, RayU, and TripathiPP. (2020). Is the collapse of the respiratory center in the brain responsible for respiratory breakdown in COVID-19 patients?. ACS Chem Neurosci, 11:1379–1381.
12.
GibsonOR, RichardsonAJ, HayesM, DuncanB, and MaxwellNS. (2015). Prediction of physiological responses and performance at altitude using the 6-Minute walk test in normoxia and hypoxia. Wilderness Environ Med, 26:205–210.
13.
GuanWJ, LiangWH, ZhaoY, LiangHR, ChenZS, LiYM, LiuXQ, ChenRC, TangCL, WangT, and others. (2020). Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. Eur Respir J, 55:2000547.
14.
HackettPH, and RoachRC. (2001). High-altitude illness. N Engl J Med, 345:107–114.
15.
JacobsonKB, RaoM, BonillaH, SubramanianA, HackI, MadrigalM, SinghU, JagannathanP, and GrantP. (2021). Patients with uncomplicated coronavirus disease 2019 (COVID-19) have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: A cautionary tale during a global pandemic. Clin Infect Dis, 73:e826–e829.
JulianCG, SubudhiAW, WilsonMJ, DimmenAC, PechaT, and RoachRC. (2011). Acute mountain sickness, inflammation, and permeability: New insights from a blood biomarker study. J Appl Physiol, 111:392–399.
18.
KeyesEL, MatherL, DukeC, RegmiN, PhelanB, PantS, StarlingJ, McElweeM, ColeD, McConnellT, PaudelP, SalladeTD, SheetsA, TwillmanD, YoungDS, and BasnyatB. (2016). Older age, chronic medical conditions and polypharmacy in Himalayan trekkers in Nepal: An epidemiologic survey and case series, J Travel Med, 23:6.
19.
LeichtfriedV, BasicD, BurtscherM, GotheRM, SiebertU, and SchobersbergerW. (2016). Diagnosis and prediction of the occurrence of acute mountain sickness measuring oxygen saturation—independent of absolute altitude?. Sleep Breath, 20:435–442.
20.
LuksAM, and GrissomCK. (2021). Return to high altitude after recovery from coronavirus disease 2019. High Alt Med Biol, 22:119–127.
21.
MairbaurlH, DehnertC, MacholzF, DanklD, SarebanM, and BergerMM. (2019). The hen or the egg: Impaired alveolar oxygen diffusion and acute high-altitude illness?. Int J Mol Sci, 20:4105.
22.
MieskeK, FlahertyG, and O'BrienT. (2009). Journeys to high altitude—risks and recommendations for travelers with preexisting medical xonditions. J Travel Med, 17:48–62.
23.
MilletGP, DebevecT, BrocherieF, BurtscherM, and BurtscherJ. (2021). Altitude and COVID-19: Friend or foe? A narrative review. Physiol Rep, 8:e14615.
ParasherA. (2021). COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J, 97:312–320.
26.
ParpaK, and MichaelidesM. (2022). Aerobic capacity of professional soccer players before and after COVID-19 infection. Sci Rep, 12:11850.
27.
PunM, TurnerR, StrapazzonG, BruggerH, and SwensonER. (2020). Lower Incidence of COVID-19 at high altitude: Facts and confounders. High Alt Med Biol, 21:217–222.
28.
RichaletJP, LarmignatP, PoitrineE, LetournelM, and Canoui-PoitrineF. (2012). Physiological risk factors for severe high-altitude illness: A prospective cohort study. Am J Respir Crit Care Med, 185:192–198.
29.
RoachRC, HackettPH, OelzO, BartschP, LuksAM, MacInnisMJ, and BaillieJK. (2018). The 2018 lake louise acute mountain sickness ccore. High Alt Med Biol, 19:4–6.
30.
SalemAM, Al KhathlanN, AlharbiAF, AlghamdiT, AlDuilejS, AlghamdiM, AlfudhailiM, AlsunniA, YarT, LatifR, RafiqueN, AsoomL, and SabitHothers. (2021). The long-term impact of COVID-19 pneumonia on the pulmonary function of survivors. Int J Gen Med, 14:3271–3280.
31.
SalmanD, VishnubalaD, Le FeuvreP, BeaneyT, KorgaonkarJ, MajeedA, and McGregorAH. (2021). Returning to physical activity after covid-19. BMJ, 372:m4721.
32.
Santos-FerreiraD, TomásR, and DoresH. (2021). Return-to-play guidelines for athletes after COVID-19 infection. JAMA Cardiol, 6:478–479.
33.
SeccombeLM, KellyPT, WongCK, RogersPG, LimS, and PetersMJ. (2004). Effect of simulated commercial flight on oxygenation in patients with interstitial lung disease and chronic obstructive pulmonary disease. Thorax, 59:966–970.
34.
SmallE, JuulN, PomeranzD, BurnsP, PhillipsC, CheffersM, and LipmanGS. (2021). Predictive capacity of pulmonary function tests for acute mountain sickness. High Alt Med Biol, 22:193–200.
35.
SolizJ, Schneider-GasserEM, Arias-ReyesC, Aliaga-RaduanF, Poma-MachicaoL, Zubieta-CallejaG, FuruyaWI, Trevizan-BaúP, DhingraRR, and DutschmannM. (2020). Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?. Respir Physiol Neurobiol, 279:103476.
36.
StavemK, GhanimaW, OlsenMK, GilboeHM, and EinvikG. (2021). Persistent symptoms 1.5–6 months after COVID-19 in non-hospitalised subjects: A population-based cohort study. Thorax, 76:405–407.
37.
StreamJO, LuksAM, and GrissomCK. (2009). Lung disease at high altitude. Expert Rev Respir Med, 3:635–650.
38.
SwensonER. (2014). The lungs in acute mountain sickness: Victim, perpetrator, or both?. Am J Med, 127:899–900.
39.
ThomasM, PriceOJ, and HullJH. (2021). Pulmonary function and COVID-19. Curr Opin Physiol, 21:29–35.
40.
ThomsonTM, CasasF, GuerreroHA, Figueroa-MujícaR, VillafuerteFC, and MachicadoC. (2021). Potential protective effect from COVID-19 conferred by altitude: A longitudinal analysis in peru during full lockdown. High Alt Med Biol, 22:209–224.
41.
WangC, JiangH, DuanJ, ChenJ, WangQ, LiuX, and WangC. (2018). Exploration of acute phase proteins and inflammatory cytokines in early stage diagnosis of acute mountain sickness. High Alt Med Biol, 19:170–177.
42.
WiersingaWJ, RhodesA, ChengAC, PeacockSJ, and PrescottHC. (2020). Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA, 324:782–793.
43.
WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. (2020). A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis, 20:192–197.
44.
XiA, ZhuoM, DaiJ, DingY, MaX, MaX, WangX, ShiL, BaiH, ZhengH, BuermbergerE, and XuJ. (2020). Epidemiological and clinical characteristics of discharged patients infected with SARS-CoV-2 on the Qinghai Plateau. J Med Virol, 92:2528–2535.
45.
YongSJ. (2021). Long COVID or post-COVID-19 syndrome: Putative pathophysiology, risk factors, and treatments. Infect Dis (Lond), 53:737–754.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
